Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
883.20
-7.48 (-0.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
October 03, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
October 02, 2023
Via
Benzinga
Stock Split Watch: Is Regeneron Pharmaceuticals Next?
September 30, 2023
If the biotech does split its stock, it will be a first for the company.
Via
The Motley Fool
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
September 29, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Examining the Quality Attributes of NASDAQ:REGN.
September 22, 2023
Why the quality investor may take a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN).
Via
Chartmill
Analyst Expectations for Regeneron Pharmaceuticals's Future
September 21, 2023
Via
Benzinga
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 9/19 Morning Trading
September 19, 2023
Via
Investor Brand Network
Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023
September 28, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
September 28, 2023
Via
Benzinga
Three Of Our Top Picks For Your Healthcare Portfolio
September 26, 2023
Amidst macro uncertainty, healthcare stocks should outperform.
Via
Talk Markets
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
September 26, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
September 18, 2023
Via
Benzinga
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
September 14, 2023
Via
Benzinga
Check Out What Whales Are Doing With REGN
September 08, 2023
Via
Benzinga
Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss
September 25, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
Via
MarketBeat
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 9/8 Morning Trading
September 08, 2023
Via
Investor Brand Network
If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,000 Today
September 05, 2023
Via
Benzinga
This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost
September 20, 2023
A higher-dose version of Eylea will help the company fight off competition and increase revenue.
Via
The Motley Fool
Exposures
Product Safety
3 Stocks to Buy to Ride Europe’s Coming Market Surge
September 19, 2023
With Europe’s markets looking to perform better in the second half of 2023, here are three European stocks to buy to ride the wave.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2023
September 15, 2023
Via
Benzinga
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
September 11, 2023
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care....
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
New to Investing? Here's How You Can Get Started With $500.
September 10, 2023
You don't have to invest a lot to start building a winning portfolio.
Via
The Motley Fool
3 Unstoppable Growth Stocks to Buy Right Now
September 09, 2023
These healthcare stocks show no signs of slowing down.
Via
The Motley Fool
Regeneron Provides Update on Planned Chief Financial Officer Transition
September 08, 2023
Robert E. Landry to retire effective February 2024; Christopher Fenimore, long-standing Senior Vice President, Head of Accounting and Controller, to assume CFO role
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Announces Updates to Board of Directors
September 08, 2023
Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., join Regeneron’s Board of Directors
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
2 Top Biotech Stocks to Buy in September
September 08, 2023
There is rarely a bad time to buy stocks with massive upside potential.
Via
The Motley Fool
Could This Biosimilar Drug Be Novartis' Next Blockbuster?
September 05, 2023
Novartis expects to submit regulatory applications for its biosimilar soon.
Via
The Motley Fool
Is REGENERON PHARMACEUTICALS (NASDAQ:REGN) suited for quality investing?
September 01, 2023
This article explores why quality investors may have a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN)
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.